SV2017005527A - Agente terapéutico para disfunción del lóbulo frontal - Google Patents
Agente terapéutico para disfunción del lóbulo frontalInfo
- Publication number
- SV2017005527A SV2017005527A SV2017005527A SV2017005527A SV2017005527A SV 2017005527 A SV2017005527 A SV 2017005527A SV 2017005527 A SV2017005527 A SV 2017005527A SV 2017005527 A SV2017005527 A SV 2017005527A SV 2017005527 A SV2017005527 A SV 2017005527A
- Authority
- SV
- El Salvador
- Prior art keywords
- demorness
- demontime
- alteration
- lewy
- disease
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
LA PRESENTE INVENCIÓN PROPORCIONA UN AGENTE TERAPÉUTICO Y/O PREVENTIVO, POR EJEMPLO, PARA DISFUNCIÓN DEL LÓBULO FRONTAL (POR EJEMPLO, ALTERACIÓN COGNITIVA (POR EJEMPLO, ALTERACIÓN COGNITIVA EN ENFERMEDAD DE PARKINSON, ALTERACIÓN COGNITIVA CAUSADA POR ESTRÁS CRÓNICO, DEMENCIA CON CUERPOS DE LEWY, PARÁLISIS SUPRANUCLEAR PROGRESIVA, DEMENCIA FRONTOTEMPORAL, Y SIMILARES), Y OTROS), ENFERMEDAD DE CUERPOS DE LEWY (POR EJEMPLO, ALTERACIÓN COGNITIVA EN ENFERMEDAD DE PARKINSON, ENFERMEDAD DIFUSA DE CUERPOS DE LEWY, DEMENCIA CON CUERPOS DE LEWY, TRASTORNO DEL MOVIMIENTO ASOCIADO CON ENFERMEDAD DE CUERPOS DE LEWY, Y SIMILARES), Y OTROS, QUE CONTIENE UN COMPUESTO REPRESENTADO POR LA FÓRMULA (I) O UNA DE SUS SALES FARMACÉUTICAMENTE ACEPTABLES COMO UN INGREDIENTE ACTIVO
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2015055532 | 2015-03-19 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SV2017005527A true SV2017005527A (es) | 2017-10-23 |
Family
ID=56919157
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SV2017005527A SV2017005527A (es) | 2015-03-19 | 2017-08-29 | Agente terapéutico para disfunción del lóbulo frontal |
Country Status (39)
| Country | Link |
|---|---|
| US (2) | US20180042910A1 (es) |
| EP (1) | EP3270923B1 (es) |
| JP (1) | JP6869893B2 (es) |
| KR (1) | KR20170129764A (es) |
| CN (1) | CN107405341A (es) |
| AR (1) | AR103972A1 (es) |
| AU (1) | AU2016234211B2 (es) |
| BR (1) | BR112017018165A2 (es) |
| CA (1) | CA2978426A1 (es) |
| CL (1) | CL2017002351A1 (es) |
| CO (1) | CO2017008814A2 (es) |
| CR (1) | CR20170405A (es) |
| CY (1) | CY1124459T1 (es) |
| DK (1) | DK3270923T3 (es) |
| DO (1) | DOP2017000206A (es) |
| EA (1) | EA032511B1 (es) |
| EC (1) | ECSP17069712A (es) |
| ES (1) | ES2884846T3 (es) |
| GE (1) | GEP20197007B (es) |
| HK (1) | HK1249059A1 (es) |
| HR (1) | HRP20211340T1 (es) |
| HU (1) | HUE055387T2 (es) |
| IL (1) | IL254196A0 (es) |
| JO (1) | JO3544B1 (es) |
| LT (1) | LT3270923T (es) |
| MX (1) | MX2017012020A (es) |
| MY (1) | MY196076A (es) |
| PE (1) | PE20171621A1 (es) |
| PL (1) | PL3270923T3 (es) |
| PT (1) | PT3270923T (es) |
| RS (1) | RS62311B1 (es) |
| SG (1) | SG11201707012YA (es) |
| SI (1) | SI3270923T1 (es) |
| SV (1) | SV2017005527A (es) |
| TN (1) | TN2017000369A1 (es) |
| TW (1) | TWI723012B (es) |
| UA (1) | UA123578C2 (es) |
| WO (1) | WO2016148308A1 (es) |
| ZA (1) | ZA201706136B (es) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113016719B (zh) * | 2019-12-24 | 2022-08-02 | 复旦大学附属华山医院 | 一种突触核蛋白病理性快动眼睡眠行为障碍模型的制备法 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1999012546A1 (fr) | 1997-09-05 | 1999-03-18 | Kyowa Hakko Kogyo Co., Ltd. | Remede contre la degenerescence neurale |
| DK1700856T3 (en) * | 2003-12-26 | 2015-12-14 | Kyowa Hakko Kirin Co Ltd | thiazole |
| EP2210891A1 (en) * | 2009-01-26 | 2010-07-28 | Domain Therapeutics | New adenosine receptor ligands and uses thereof |
| TWI548411B (zh) * | 2009-04-28 | 2016-09-11 | Kyowa Hakko Kirin Co Ltd | Exercise disorder treatment |
| UA110097C2 (uk) * | 2009-09-02 | 2015-11-25 | Терапевтичний агент для лікування розладів настрою | |
| UA113383C2 (xx) * | 2009-09-02 | 2017-01-25 | Терапевтичний агент для лікування тривожних розладів | |
| WO2012060844A1 (en) | 2010-11-05 | 2012-05-10 | Biotie Therapies, Inc | A2a antagonists as cognition and motor function enhancers |
-
2016
- 2016-03-17 JO JOP/2016/0045A patent/JO3544B1/ar active
- 2016-03-18 UA UAA201709985A patent/UA123578C2/uk unknown
- 2016-03-18 GE GEAP201614604A patent/GEP20197007B/en unknown
- 2016-03-18 PT PT167651355T patent/PT3270923T/pt unknown
- 2016-03-18 LT LTEP16765135.5T patent/LT3270923T/lt unknown
- 2016-03-18 EP EP16765135.5A patent/EP3270923B1/en active Active
- 2016-03-18 BR BR112017018165A patent/BR112017018165A2/pt not_active Application Discontinuation
- 2016-03-18 SI SI201631316T patent/SI3270923T1/sl unknown
- 2016-03-18 TW TW105108544A patent/TWI723012B/zh not_active IP Right Cessation
- 2016-03-18 AU AU2016234211A patent/AU2016234211B2/en not_active Ceased
- 2016-03-18 CA CA2978426A patent/CA2978426A1/en not_active Abandoned
- 2016-03-18 RS RS20211061A patent/RS62311B1/sr unknown
- 2016-03-18 MX MX2017012020A patent/MX2017012020A/es unknown
- 2016-03-18 ES ES16765135T patent/ES2884846T3/es active Active
- 2016-03-18 MY MYPI2017703320A patent/MY196076A/en unknown
- 2016-03-18 DK DK16765135.5T patent/DK3270923T3/da active
- 2016-03-18 PE PE2017001525A patent/PE20171621A1/es unknown
- 2016-03-18 HU HUE16765135A patent/HUE055387T2/hu unknown
- 2016-03-18 CR CR20170405A patent/CR20170405A/es unknown
- 2016-03-18 AR ARP160100730A patent/AR103972A1/es unknown
- 2016-03-18 PL PL16765135T patent/PL3270923T3/pl unknown
- 2016-03-18 US US15/558,240 patent/US20180042910A1/en not_active Abandoned
- 2016-03-18 SG SG11201707012YA patent/SG11201707012YA/en unknown
- 2016-03-18 WO PCT/JP2016/059788 patent/WO2016148308A1/en active Application Filing
- 2016-03-18 TN TNP/2017/000369A patent/TN2017000369A1/en unknown
- 2016-03-18 CN CN201680012849.8A patent/CN107405341A/zh active Pending
- 2016-03-18 KR KR1020177026576A patent/KR20170129764A/ko not_active Application Discontinuation
- 2016-03-18 JP JP2017547186A patent/JP6869893B2/ja active Active
- 2016-03-18 EA EA201792070A patent/EA032511B1/ru unknown
-
2017
- 2017-08-29 IL IL254196A patent/IL254196A0/en unknown
- 2017-08-29 SV SV2017005527A patent/SV2017005527A/es unknown
- 2017-08-29 CO CONC2017/0008814A patent/CO2017008814A2/es unknown
- 2017-09-08 ZA ZA2017/06136A patent/ZA201706136B/en unknown
- 2017-09-11 DO DO2017000206A patent/DOP2017000206A/es unknown
- 2017-09-15 CL CL2017002351A patent/CL2017002351A1/es unknown
- 2017-10-18 EC ECIEPI201769712A patent/ECSP17069712A/es unknown
-
2018
- 2018-07-11 HK HK18108966.3A patent/HK1249059A1/zh unknown
-
2021
- 2021-08-20 HR HRP20211340TT patent/HRP20211340T1/hr unknown
- 2021-08-25 CY CY20211100762T patent/CY1124459T1/el unknown
- 2021-09-03 US US17/466,772 patent/US20210393606A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DOP2016000286A (es) | Compuesto heterocíclico que contiene nitrógeno | |
| CO2019013707A2 (es) | Polinucleótidos de aadc para el tratamiento de la enfermedad de parkinson | |
| CR20160485A (es) | Compuesto de ciclopropanamina y sus usos | |
| BR112017009497A2 (pt) | polinucleotídeos de aadc para o tratamento da doença de parkinson | |
| UY35276A (es) | Nuevos compuestos que inhiben la actividad de Lp-PLA2 | |
| CL2019000625A1 (es) | Combinación de agonistas de fxr. | |
| CL2016000019A1 (es) | Compuestos derivados de dihidroxifenilo deuterado o una sal de los mismos; composición farmacéutica que los comprende y su uso para el tratamiento de trastornos mediados por neurotransmisores tales como hipotensión, trastornos del sueño, enfermedad de alzheimer y depresión. | |
| DOP2016000290A (es) | Compuestos heteroaromáticos y su uso como ligandos de dopamina d1 | |
| UY37729A (es) | NUEVOS COMPUESTOS QUE INHIBEN LA ACTIVIDAD DE Nav1.7 | |
| ECSP16086247A (es) | (s)-pirlindole y sus sales farmacéuticamente aceptables para uso en medicina | |
| DOP2016000289A (es) | Compuestos heteroaromáticos y su uso como ligandos de dopamina d1 | |
| CL2016000884A1 (es) | Derivados de piperazina y su uso como medicamento. | |
| ECSP16086232A (es) | (r) -pirlindole y sus sales farmacéuticamente aceptables para uso en medicina | |
| CO2021007442A2 (es) | Compuesto de 1,3,4-oxadiazolona y fármaco | |
| CL2017002229A1 (es) | Inhibidores de bace1. | |
| SV2017005527A (es) | Agente terapéutico para disfunción del lóbulo frontal | |
| CO2020001792A2 (es) | Combinaciones farmacéuticas | |
| BR112018072255A2 (pt) | azasteroides para tratamento de tuberculose | |
| UY35989A (es) | Uso de paricalcitol en el tratamiento de la anemia inflamatoria | |
| ECSP18006622A (es) | Derivados de 2,3-dihidro-4h-1,3-benzoxazin-4-ona como moduladores de receptor muscarinico m1 cholinergico | |
| BR112018077112A2 (pt) | uso de liso-gb1 como alvo capaz de ser modulado por um fármaco | |
| AR110957A1 (es) | Agente terapéutico oral para tiroides | |
| TR201719926A2 (tr) | Farmasöti̇k olarak kabul edi̇lebi̇li̇r li̇tyum tuzlari ve c vi̇tami̇ni̇ i̇çeren farmasöti̇k bi̇leşi̇mler | |
| BR112016030599A8 (pt) | novos derivados de aminoalquilbenzotiazepina e suas utilizações | |
| BR112016024918A2 (pt) | ?uso de uma droga? |